Thermo Fisher Scientific Inc. (TMO)
Overview
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date (Estimated) | 2026-01-29 |
| Earnings Call (Estimated) | 2025-10-22 |
| Avg EPS Estimate | 6.45 |
| Low EPS Estimate | 6.388 |
| High EPS Estimate | 6.52 |
| Revenue | |
| Avg Revenue Forecast | 11,952,216,890 |
| Low Revenue Forecast | 11,819,000,000 |
| High Revenue Forecast | 12,008,900,000 |
TMO Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $3,545,999,872 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.946 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.498 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $35,680,002,048 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
TMO Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $10,835,000,320 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $7,650,999,808 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $4,696,750,080 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 41.39% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 19.28% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 15.02% | Net profit margin, which reflects overall profitability. |
TMO Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 69.75% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $35,680,002,048 | Used together with cash and EBITDA to assess debt-paying ability. |
TMO Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 4.90% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.50% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for TMO (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $567.64 | Latest stock trading price |
| Price Target (High) | $675 | Analyst highest expected price |
| Price Target (Low) | $533.16 | Analyst lowest expected price |
| Price Target (Average) | $613.58 | Average target price across analysts |
| Price Target (Median) | $620 | Median of target prices |
| Average Rating Score | 1.68 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 21 | Number of analysts providing estimates |
| Cash Holdings | $3,545,999,872 | Total cash held by the company |
| Cash per Share | $9.44 | Cash value per outstanding share |
| Total Debt | $35,680,002,048 | Company's total debt |
| Quick Ratio | 0.946 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.498 | Overall short-term liquidity |
| Debt/Equity Ratio | 69.75% | Leverage ratio: Debt / Equity |
| EBITDA | $10,835,000,320 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $43,735,998,464 | Total company revenue |
| Revenue per Share | $115.398 | Total revenue divided by shares outstanding |
| Gross Profit | 41.39% | Revenue minus cost of goods sold |
| Return on Assets | 4.94% | Net income / Total assets |
| Return on Equity | 13.12% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.50% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 4.90% | Year-over-year revenue growth |
| Gross Margin | 41.39% | Gross profit / Total revenue |
| EBITDA Margin | 24.77% | EBITDA / Revenue |
| Operating Margin | 19.28% | Operating income / Revenue |
| Profit Margin | 15.02% | Net income / Revenue |
| Free Cash Flow | $4,696,750,080 | Cash left after capital expenditures |
| Operating Cash Flow | $7,650,999,808 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |